<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04854486</url>
  </required_header>
  <id_info>
    <org_study_id>LCH-2-112020</org_study_id>
    <nct_id>NCT04854486</nct_id>
  </id_info>
  <brief_title>Impact of GSE and Xylitol (Xlear) on COVID-19 Symptoms and Time to PCR Negativisation in COVID-19 Patients</brief_title>
  <official_title>Impact of GSE and Xylitol (Xlear) in Symptoms and Time to PCR Negativisation of Patients With Acute COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Larkin Community Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Larkin Community Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial aims to ascertain the impact of GSE and Xylitol (XLEAR) in decreasing the&#xD;
      time of negativisation in PCR testing in patients with COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 16, 2021</start_date>
  <completion_date type="Anticipated">November 16, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Placebo controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of time to negativisation via PCR</measure>
    <time_frame>Baseline and 7 days</time_frame>
    <description>There will be a change in the time to negativisation via PCR as compared to the average 14-day time to negative result.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Xylitol + GSE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GSE and Xylitol</intervention_name>
    <description>Participants are given the experimental treatment to be used for 7 days.</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control Placebo</intervention_name>
    <description>Saline</description>
    <arm_group_label>Control placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Adults of ages 18 to 90 years of both sexes&#xD;
&#xD;
          -  With positive SARS-CoV-2 carriage confirmed by nasopharyngeal PCR&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  1- Mild symptoms: Minimum respiratory symptoms or asymptomatic plus positive test&#xD;
&#xD;
          -  2- Moderate symptoms: Respiratory symptoms such as cough, mild shortness of breath&#xD;
             with mild oxygen desaturation(room air SpO2 &lt;92% and &gt;88% or &lt;88% corrected to &gt;92%&#xD;
             with 2lt of oxygen)&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Patients with Severe symptoms: Hypoxia (SpO2 &lt;88% not corrected by 2 lt nc oxygen)&#xD;
             plus severe shortness of breath (excluded)&#xD;
&#xD;
          -  Patient with very low viral load (threshold cycle [Ct] &gt; 25 per PCR).&#xD;
&#xD;
          -  Known hypersensitivity to one of the constituents, particularly to xylitol or GSE&#xD;
&#xD;
          -  Under 18 years of age&#xD;
&#xD;
          -  Women of childbearing age who are pregnant, breastfeeding mothers, and intend to&#xD;
             become pregnant during the study period; unwilling/unable to take a pregnancy test.&#xD;
&#xD;
          -  Unable to provide informed consent or decline to consent or unwillingness to adhere to&#xD;
             the Standard of Care protocol.&#xD;
&#xD;
          -  Patients with severe symptoms -Hypoxia (SpO2 &lt;88% not corrected by 2 liter non-&#xD;
             concentrated oxygen) plus severe shortness of breath&#xD;
&#xD;
          -  History of immunodeficiency or are currently receiving immunosuppressive therapy.&#xD;
&#xD;
          -  Have had a planned surgical procedure within the past 12 weeks.&#xD;
&#xD;
          -  Already part of this trial, recruited at a different hospital.&#xD;
&#xD;
          -  Patient unable to perform oro-nasopharyngeal decolonization&#xD;
&#xD;
          -  Patients with acute exacerbation of severe comorbidities like heart disorders Chronic&#xD;
             Obstructive Pulmonary Disease (COPD), Heart Failure New York Heart Association (NYHA)&#xD;
             Class 3 and 4 and/or diseases with severe oxygenation problems&#xD;
&#xD;
          -  Patients on Remdesivir and/or other clinical trials.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Roboam R Aguirre, MD, DBA</last_name>
    <phone>305-284-7608</phone>
    <email>raguirre@larkinhospital.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Larkin Community Hospital Palm Springs Campus</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Roboam R Aguirre, MD, DBA</last_name>
      <phone>305-284-7608</phone>
      <email>raguirre@larkinhospital.com</email>
    </contact>
    <contact_backup>
      <last_name>Marcos Sanchez-Gonzalez, MD, PhD</last_name>
      <email>masanchez@larkinhospital.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Larkin Community Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Roboam R Aguirre, MD, DBA</last_name>
      <phone>305-284-7608</phone>
      <email>raguirre@larkinhospital.com</email>
    </contact>
    <contact_backup>
      <last_name>Marcos Sanchez-Gonzalez, MD, PhD</last_name>
      <email>masanchez@larkinhospital.com</email>
    </contact_backup>
    <investigator>
      <last_name>Gustavo Ferrer, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 17, 2021</study_first_submitted>
  <study_first_submitted_qc>April 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Larkin Community Hospital</investigator_affiliation>
    <investigator_full_name>Gustavo Ferrer, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>intranasal spray</keyword>
  <keyword>Covid19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

